Form 8-K - Current report:
SEC Accession No. 0000950170-22-016015
Filing Date
2022-08-09
Accepted
2022-08-09 16:01:33
Documents
14
Period of Report
2022-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rphm-20220809.htm   iXBRL 8-K 54770
2 EX-99.1 rphm-ex99_1.htm EX-99.1 352172
3 GRAPHIC img187185602_0.jpg GRAPHIC 176365
  Complete submission text file 0000950170-22-016015.txt   782328

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rphm-20220809_lab.xml EX-101.LAB 13342
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rphm-20220809_pre.xml EX-101.PRE 9846
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rphm-20220809.xsd EX-101.SCH 2478
8 EXTRACTED XBRL INSTANCE DOCUMENT rphm-20220809_htm.xml XML 4717
Mailing Address 18575 JAMBOREE ROAD SUITE 275-S IRVINE CA 92612
Business Address 18575 JAMBOREE ROAD SUITE 275-S IRVINE CA 92612 (858) 283-0280
Reneo Pharmaceuticals, Inc. (Filer) CIK: 0001637715 (see all company filings)

EIN.: 472309515 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40315 | Film No.: 221148077
SIC: 2834 Pharmaceutical Preparations